Even if there is still ongoing several gaps for detecting the different resistance mechanisms of ALK inhibitors in ALK positive treated lung cancer patients (notably the histological type transformation of the tumors, some gene amplifications or fusions, etc.), the LB presents currently strong advantages at tumor progression, such as those described above. This evidence concerns the gene ALK and neoplasm.